Home » Therapeutic Areas » Obesity Metabolic Diseases

Obesity and Metabolic Diseases Imaging For Clinical Trials

Obesity and Metabolic Diseases Imaging CRO

As a specialist imaging CRO for obesity and metabolic disease trials, we provide standardized quantitative imaging assessments, including MRI-PDFF, MR elastography and body composition analysis, to support non-invasive evaluation of treatment effects.

0

Years of Imaging Expertise!

0

Clinical Trials Supported

Global

Site & Investigator Network

Compliance & Certificates

SOC 2 TYPE II

HHS-Seal

GDPR

FDA 21 CFR Part 11

ISO 13485

Non-Invasive Liver and Body Composition Endpoints

Imaging endpoints in obesity and metabolic trials

In obesity and metabolic disease trials, quantitative imaging provides non-invasive measures that can complement clinical, biochemical and histological assessments. MRI-PDFF enables standardized quantification of liver fat, while MR elastography provides a non-invasive assessment of liver stiffness, reducing the need for repeated invasive procedures in appropriate study designs.

The development of GLP-1 receptor agonists and dual- and multi-agonist therapies has increased interest in imaging-based assessment of changes in adipose tissue, lean mass and ectopic fat. Visceral and subcutaneous adipose tissue, body composition and fat deposition in organs such as the liver, pancreas and muscle can be quantified longitudinally to support the evaluation of treatment effects.

IAG delivers standardized imaging protocols and centralized quantitative analysis for obesity, MASH and metabolic disease programs, integrating liver, body composition and other relevant imaging measures within a study-specific imaging strategy.

Learn more

What our metabolic imaging team does

Obesity and Metabolic Imaging Capabilities

Quantitative liver and body composition analysis, acquisition standardization across MRI systems and reader qualification — tailored to GLP-1, dual- and multi-agonist and combination programs.

Non-invasive liver assessment

MRI-PDFF for quantitative assessment of liver fat and MR elastography for liver stiffness assessment, providing standardized imaging measures that can complement or, where appropriate, reduce reliance on repeated biopsy.

Body composition quantification

Quantitative assessment of visceral and subcutaneous adipose tissue, lean mass and regional fat distribution, including ectopic fat in the liver, pancreas and skeletal muscle where relevant to the study.

Obesity and metabolic drug development

Imaging strategies tailored to GLP-1 receptor agonists, dual- and multi-agonist therapies and combination treatment programs.

Study Phases

How Image Analysis Group Supports Obesity and Metabolic Trials

Quantitative liver and body composition imaging, scaled from exploratory analysis to registrational delivery.

Collect & Hold

Prospective or retrospective collection MRI, CT and DXA collection and secure archival — quantified when your endpoint strategy is finalized.

Collect & Hold

Early Phase Trials

MRI-PDFF and body composition analysis to size the treatment effect and inform endpoint selection for later phases.

Early Phase Trials

Late Phase Trials

Standardized quantification of liver fat, liver stiffness and body composition across MRI systems and global sites.

Late Phase Trials

RWE & AI Studies

Submission-ready quantitative datasets, TFLs and variability analyses for liver and body composition endpoints.

RWE & AI Studies

The experts behind your reads

The Imaging Experts

Quantitative liver MRI pioneers, hepatologists and obesity researchers who set acquisition standards and analysis methodology for MASH, obesity and metabolic bone programs.

Scientific Advisor — Obesity and Liver Diseases Expert

Scientific Advisor — GLP-1, Osteoarthritis and Pain

Chief, Section of Gastroenterology, Hepatology and Nutrition | Director, IBD Center

Measures and modalities we work in

Metabolic Quantitative Imaging Measures

MRI-PDFF, MR elastography and shear-wave elastography, VAT/SAT and body composition quantification, plus Trabecular Bone Score, vertebral fracture grading and DXA/QCT bone measures.

Criterion

Applies to

MRI-PDFF

Liver fat quantification

MR elastography (MRE)

Non-invasive fibrosis assessment

Shear-wave elastography

Fibrosis

VAT / SAT quantification

Visceral and subcutaneous adipose tissue

Body composition analysis

Quantification of fat mass, lean mass and regional tissue distribution

Trabecular bone score

Bone health

Vertebral fracture grading

Bone health

DXA T-score / QCT

Bone mineral density

MR spectroscopy metabolite profiling

Rare metabolic disorders

Metabolic Indications We Support

Indications We Cover

Obesity, MASLD/MASH, rare metabolic disorders and metabolic bone disease — with liver, body composition and bone measures combined to fit the endpoint.

Obesity

With GLP-1 and multi-agonist therapies, what changes matters as much as how much. We quantify visceral and subcutaneous adipose tissue, lean mass and regional fat distribution longitudinally, standardized across MRI systems and sites.

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD/MASH)

MRI-PDFF and MR elastography provide repeatable measures of liver fat and stiffness, reducing reliance on repeat biopsy in appropriate designs. We standardize acquisition across scanner platforms and centralize quantitative analysis for consistent longitudinal comparison.

Rare Metabolic Disorders

Small cohorts and multisystem involvement demand sensitive, reproducible measures. We apply MR spectroscopy metabolite profiling, organ volumetry and quantitative MRI tailored to the specific disease mechanism.

Metabolic Bone Disease

Bone endpoints hinge on DXA comparability across sites and hardware. We harmonize Hologic and GE systems with phantom-based QC and deliver BMD T-scores, Trabecular Bone Score, vertebral fracture grading and QCT measures.

One Platform for Liver and Body Composition Endpoints

Why Sponsors Choose Image Analysis Group

DYNAMIKA™ standardizes quantitative analysis of liver fat, liver stiffness and body composition across scanner platforms and sites, with analyst qualification and a complete audit trail.

Centralized, secure data collection

DYNAMIKA™ unifies global imaging into a single cloud-native environment — GxP-validated, SOC 2 Type II and 21 CFR Part 11 compliant.

Real-time visibility and oversight

24/7 access to imaging status for every stakeholder, with site and reader performance tracked as the study runs.

Quality control and automated anonymization

Automated checks on receipt produce de-identified, QC-passed datasets before any read begins.

Consistent, standardized reads

Protocol-driven central reviews deliver standardized quantitative assessment of liver fat, liver stiffness and body composition, using study-specific acquisition and analysis methods designed to support consistency across sites and MRI systems.

Obesity and Metabolic Diseases

Reader management and audit trails

Readers and analysts are qualified against the study-specific assessment and quantification methodology for each imaging measure. Assignment, blinding and adjudication workflows are managed in-platform, with every action recorded in a complete audit trail.